Monday 8th May 2017 |
Text too small? |
Blis Technologies missed guidance for a maiden annual profit, having already downgraded the earnings outlook in February, as sales growth slowed to 16 percent.
The Dunedin-based company reported a net loss of $24,000 in the 12 months ended March 31, narrowing from a loss of $816,000 a year earlier. Blis had already warned the market in February that pre-tax profit wasn't going to meet the $700,000 forecast due to significant reductions in purchases by three major customers, but was still expecting to generate a net surplus.
Sales rose to $6.5 million from $5.7 million a year earlier, slowing from the 41 percent increase in revenue in the first half. Earnings before interest, tax, depreciation, and amortisation was a surplus of $586,000, compared to a deficit of $347,000 a year earlier. Before the February downgrade, Blis had been projecting revenue of $8 million.
The board decided to put off recognising $1.3 million tax asset because of the net loss, chairman Peter Fennessy said in a statement.
Blis was set up to commercialise probiotic bacteria for use in consumer products for oral health, colds and flu and is focused on managing growth and continuing its strategy of securing regulatory approvals market by market. It first listed in 2001.
The shares last traded at 3.8 cents, valuing Blis at $42.1 million. They've dropped 5 percent so far this year.
(BusinessDesk)
No comments yet
Second St John withdrawal of labour takes effect tomorrow with further strikes likely
Sanford Appoints Independent Director
CRP ADVISES CLOSURE OF SHARE OFFER TO EXISTING INVESTOR
Devon Funds Morning Note - 14 August 2024
OCR 5.25% - Monetary restraint tempered as inflation converges on target
Consumers still need due diligence as new deposit takers emerge.
Woolworths strike: staff asked to dress up in Disney costumes for a week on their own dollar
Turners Invests in Quashed Online Insurance Platform
PGW Reports on Challenging Year
Arvida Announces Executive Team Changes